Veach, Darren

Publications

Sort by

Co-Author Network

selected publications

Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy. Proceedings of the National Academy of Sciences of the United States of America. 2020 Academic Article GET IT
Times cited: 10
Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 19
ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts. Molecular pharmaceutics. 2018 Academic Article GET IT
Times cited: 5
Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nature communications. 2018 Academic Article GET IT
Times cited: 33
Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. JAMA oncology. 2018 Academic Article GET IT
Times cited: 81
In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME). Oncotarget. 2017 Academic Article GET IT
Times cited: 19
Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis. Science translational medicine. 2016 Academic Article GET IT
Times cited: 18
Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016 Academic Article GET IT
Times cited: 12
Remodeling the Vascular Microenvironment of Glioblastoma with α-Particles. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016 Academic Article GET IT
Times cited: 19
Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling. EJNMMI research. 2016 Academic Article GET IT
Times cited: 30
Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 44
Fluorine-labeled dasatinib nanoformulations as targeted molecular imaging probes in a PDGFB-driven murine glioblastoma model. Neoplasia (New York, N.Y.). 2012 Academic Article GET IT
Times cited: 40
Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor. Proceedings of the National Academy of Sciences of the United States of America. 2012 Academic Article GET IT
Times cited: 26
Dosimetry of 18F-labeled tyrosine kinase inhibitor SKI-249380, a dasatinib-tracer for PET imaging. Molecular imaging and biology. 2012 Academic Article GET IT
Times cited: 10
A magnetic bead-based protein kinase assay with dual detection techniques. Analytical biochemistry. 2010 Academic Article GET IT
Times cited: 16
Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib. Molecular cancer research : MCR. 2010 Academic Article GET IT
Times cited: 33
Cell treatment and lysis in 96-well filter-bottom plates for screening Bcr-Abl activity and inhibition in whole-cell extracts. Journal of biomolecular screening. 2010 Academic Article GET IT
Times cited: 3
(124)I-iodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2010 Academic Article GET IT
Times cited: 9
Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 74
Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorganic & medicinal chemistry letters. 2009 Academic Article GET IT
Times cited: 11
A solid-phase Bcr-Abl kinase assay in 96-well hydrogel plates. Analytical biochemistry. 2007 Academic Article GET IT
Times cited: 19
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. The Journal of clinical investigation. 2007 Academic Article GET IT
Times cited: 584
Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib. Journal of medicinal chemistry. 2007 Academic Article GET IT
Times cited: 36
Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 120
L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. International journal of cancer. 2007 Academic Article GET IT
Times cited: 196
Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells. Proteomics. 2006 Academic Article GET IT
Times cited: 39
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proceedings of the National Academy of Sciences of the United States of America. 2006 Academic Article GET IT
Times cited: 98
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proceedings of the National Academy of Sciences of the United States of America. 2006 Academic Article GET IT
Times cited: 109
Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nature medicine. 2005 Academic Article GET IT
Times cited: 184
Synthesis and in vitro examination of [124I]-, [125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors. Nuclear medicine and biology. 2005 Academic Article GET IT
Times cited: 16
DNA photocleavage and biological activity of a pyrene dihydrodioxin. Bioorganic & medicinal chemistry letters. 2005 Academic Article GET IT
Times cited: 9
PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood. 2005 Academic Article GET IT
Times cited: 62
A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood. 2004 Academic Article GET IT
Times cited: 73
Caenorhabditis elegans ABL-1 antagonizes p53-mediated germline apoptosis after ionizing irradiation. Nature genetics. 2004 Academic Article GET IT
Times cited: 58
Enteropathogenic Escherichia coli use redundant tyrosine kinases to form actin pedestals. Molecular biology of the cell. 2004 Academic Article GET IT
Times cited: 98
A fluorine-labeled methotrexate as a probe for monitoring tumor antifolate pharmacokinetics: synthesis, in vitro cytotoxicity, and pilot in vivo 19F magnetic resonance spectra. Molecular cancer therapeutics. 2003 Academic Article GET IT
Times cited: 4
Gleevec inhibits beta-amyloid production but not Notch cleavage. Proceedings of the National Academy of Sciences of the United States of America. 2003 Academic Article GET IT
Times cited: 176
Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors. Cancer research. 2003 Academic Article GET IT
Times cited: 73
Two distinct phosphorylation pathways have additive effects on Abl family kinase activation. Molecular and cellular biology. 2003 Academic Article GET IT
Times cited: 112
Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell. 2003 Academic Article GET IT
Times cited: 638
Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer research. 2002 Academic Article GET IT
Times cited: 154
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer research. 2002 Academic Article GET IT
Times cited: 868
Fluorescent monitoring of kinase activity in real time: development of a robust fluorescence-based assay for Abl tyrosine kinase activity. Bioorganic & medicinal chemistry letters. 2001 Academic Article GET IT
Times cited: 25

more ...

less ...

Background

education and training

Ph.D., University of Cincinnati 2001
B.A., Wittenberg University 1992

Contact

full name

Darren Veach

VIVO Weill Cornell Medical College

Darren Veach Assistant Professor of Radiochemistry and Radiopharmacy in Radiology

Publications

selected publications

Background

education and training

Contact

full name